Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., March 04, 2021 – Vaxart, a clinical-stage biotechnology company focused on oral recombinant vaccines, announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9 through the conference portal and on Vaxart’s website afterward. Vaxart is developing several oral vaccines targeting coronavirus, Norovirus, seasonal influenza, respiratory syncytial virus (RSV), and human papillomavirus (HPV), aiming to revolutionize vaccine delivery and storage.

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal available here, starting at 7 a.m. ET on Tuesday, March 9, 2021 and on Vaxart’s website after the conference. The Company will also participate in one-on-one investor meetings at the conference.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts
Brant Biehn Vaxart, Inc. 650 550 3500 IR@vaxart.com	David R. Holmes LifeSci Advisors, LLC 646 970 4995 dholmes@lifesciadvisors.com

FAQ

What is the date of Vaxart's presentation at the H.C. Wainwright Global Life Sciences Conference?

Vaxart's presentation is scheduled for March 9, 2021, at the H.C. Wainwright Global Life Sciences Conference.

How can I access Vaxart's presentation from the conference?

Vaxart's presentation will be available on-demand starting at 7 a.m. ET on March 9, 2021, through the conference portal and on Vaxart’s website afterward.

What type of vaccines is Vaxart developing?

Vaxart is developing oral recombinant vaccines targeting coronavirus, Norovirus, seasonal influenza, respiratory syncytial virus (RSV), and a therapeutic vaccine for human papillomavirus (HPV).

What is the significance of Vaxart's tablet vaccine delivery system?

Vaxart's tablet vaccine delivery system allows for storage and shipment without refrigeration and eliminates the risk of needle-stick injuries.

What potential does Vaxart see in its proprietary technology?

Vaxart believes its proprietary tablet vaccine delivery platform can deliver recombinant vaccines effectively, positioning the company to develop oral versions of existing vaccines and new recombinant vaccines.